HH3806 / HaiHe Biopharma 
Welcome,         Profile    Billing    Logout  

1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HH3806 / HaiHe Biopharma
ACTRN12622001339741: A First-in-Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients With Advanced Tumors

Recruiting
1
36
 
Tigermed Australia Pty Ltd, Taizhou Haihe Pharmaceutical Co.,Ltd.
Solid Tumors, relapsed/refractory Non-Hodgkin’s lymphomas (NHL)
 
 

Download Options